drugset / Trial / NCT00834405

Leflunomide 20 mg Tablets, Non-Fasting

NCT00834405

Phase 1 Completed 37 enrolled Teva Pharmaceuticals USA
RandomizedParallel-groupOpen-labelOther

Summary

The objective of this study is to compare the relative bioavailability of leflunomide 20 mg tablets (manufactured by TEVA Pharmaceutical Industries, Ltd. and distributed by TEVA Pharmaceuticals USA) with that of ARAVA 20 mg tablets (Aventis) in healthy, adult, non-smoking subjects \[females (who are unable to become pregnant) and vasectomized males\] under non-fasting conditions.

Timeline

Start
2002-04
Primary completion
2002-05
Completion
2002-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Leflunomide Small molecule 20 mg

Indications

No indication recorded.